Influence of Dexmedetomidine on inflammatory factors in patients with tongue cancer during perioperative period

doi:10.3877/cma.j.issn.1674-1366.2016.01.009

Abstract

Abstract:

Objective

The aim of the study was to evaluate the effects of Dexmedetomidine (Dex) on plasma hs-CRP, interleukin-1 (IL-1) , IL-6, tumor necrosis factor-α (TNF-α) in patients undergoing radical resection of tongue cancer.

Methods

Sixty patients with tongue cancer undergoing surgery with general anesthesia (ASAⅠ~Ⅱ) were included. They were randomly divided into Dex group and control group with each of 30. Both group of patients were rapidly induced with pro- pofol, remifentanil and cis-atracurium and followed by sevoflu- ran, remifentanil and cis-atracurium for maintenance. In addition to sevofluran, remifentanil and cis-atracurium, the Dex group also received Dexmedetomidine for maintenance. ELISA was used to examine the plasma level of hs-CRP, IL-1, IL-6, TNF-α at 30 minutes before anesthesia induction (T0) , before skin incision (T1) , 1 hour of operation (T2) , immediately postoperation (T3) , 6 h postoperation (T4) and 24 h postoperation (T5) .

Results

Plasma hs-CRP, IL-1, IL-6, TNF-α levels were obviously higher at T2, T3, T4 and T5 than at T0 and T1 in both groups (P<0.01) , with peak level at T3 and gradually decreasing postopertation. Compared with control group, plasma hs-CRP, IL-1, IL-6, TNF-α were markedly decreased in the Dex group at T2, T3, T4 and T5 (P<0.01) .

Conclusion

Dexmedetomidine could inhibit inflammation in patients undergoing radical resection of tongue cancer.

Key words: Dexmedetomidine, Tongue neoplasms, Inflammation

Qiaomei Wu, Qing Xu, Zhi Wu, Yuansheng Zhai. Influence of Dexmedetomidine on inflammatory factors in patients with tongue cancer during perioperative period[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2016, 10(01): 51-54.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhkqyxyjzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1366.2016.01.009

https://zhkqyxyjzz.cma-cmc.com.cn/EN/Y2016/V10/I01/51

Figures/Tables 2

References 17

[1]	Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence[J]. Br J Anaesth，2010，105(2):106-115.
[2]	Ramsay MA, Luterman DL. Dexmedetomidine as a total intravenous anesthetic agent[J]. Anesthesiology，2004，101(3):787-790.
[3]	Preslaski CR, Mueller SW, Wempe MF，et al. Stability of dexmedetomidine in polyvinyl chloride bags containing 0.9% sodium chloride injection[J]. Am J Health Syst Pharm，2013，70(15):1336-1341.
[4]	Omoigui S. The biochemical origin of pain—proposing a new law of pain：the origin of all pain is inflammation and the inflammatory response. Part 1 of 3—a unifying law of pain[J]. Med Hypotheses，2007，69(1):70-82.
[5]	Sheeran P, Hall GM. Cytokines in anaesthesia[J]. Br J Anaesth，1997，78(2):201-219.
[6]	Vittimberga FJ Jr, Foley DP, Meyers WC，et al. Laparoscopic surgery and the systemic immune response[J]. Ann Surg，1998，227(3):326-334.
[7]	Lacy AM, Garcia-Valdecasas JC, Delgado S，et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer：a randomised trial[J]. Lancet，2002，359(9325):2224-2229.
[8]	Tsuchiya Y, Sawada S, Yoshioka I，et al. Increased surgical stress promotes tumor metastasis[J]. Surgery，2003，133(5):547-555.
[9]	许忠玲，范冰冰，郭华，等.右美托咪定对重症颅脑损伤患者围术期血浆S蛋白100B及炎性细胞因子的影响[J].临床麻醉学杂志，2012，28(9):872-874.
[10]	Parikh DA, Kolli SN, Karnik HS，et al. A prospective randomized double-blind study comparing dexmedetomidine vs. combination of midazolam-fentanyl for tympanoplasty surgeryunder monitored anesthesia care[J]. J Anaesthesiol Clin Pharmacol，2013，29(2):173-178.
[11]	Przewratil P, Sitkiewicz A, Andrzejewska E. Serum levels of basic fibroblastic growth factor（bFGF）in children with vascular anomalies：Another insight into endothelial growth[J]. Clin Biochem，2010，43(10-11):863-867.
[12]	蒋丽，白华，韦妙成，等.子宫肌瘤腹腔镜与开腹切除术围术期TNF-α、IL-6和IL-10的变化[J].中国妇幼保健，2011，26(21):3231-3233.
[13]	Franke A, Lante W, Kupser S，et al. Procalcitonin levels after different types of conventional thoracic surgery[J]. Thorac Cardiovasc Surg，2008，56(1):46-50.
[14]	刘颖赵，孙长根. TNF-α、IL-6、PLA2在严重骨折合并创伤患者中的变化及损伤控制技术的影响[J].海南医学院学报，2015，21(4):501-503.
[15]	Bhana N, Goa KL, McClellan KJ. Dexmedetomidine[J]. Drugs，2000，59(2):263-268.
[16]	吉春玲，瞿祥，任亦频，等.右美托咪定对脓毒症大鼠心肌组织水通道蛋白-1及炎症细胞因子水平的干预作用[J].中国中西医结合急救杂志，2014，21(4):266-269.
[17]	Li S, Yang Y, Yu C，et al. Dexmedetomidine analgesia effects in patients undergoing dental implant surgery and its impact on postoperative inflammatory and oxidative stress[J]. Oxid Med Cell Longev，2015:186736.

组别	例数（男/女）	年龄（岁）	体重(kg)	手术时间(min)	MAP(mmHg)	心率（次/分钟）
Dex组	30(16/14)	60.3 ± 9.7	60.09 ± 4.30	120.37 ± 17.03	92.1 ± 2.6	88 ± 4
对照组	30(15/15)	60.2 ± 9.2	60.05 ± 3.24	115.38 ± 22.28	91.0 ± 3.2	90 ± 4

组别	例数（男/女）	年龄（岁）	体重(kg)	手术时间(min)	MAP(mmHg)	心率（次/分钟）
Dex组	30(16/14)	60.3 ± 9.7	60.09 ± 4.30	120.37 ± 17.03	92.1 ± 2.6	88 ± 4
对照组	30(15/15)	60.2 ± 9.2	60.05 ± 3.24	115.38 ± 22.28	91.0 ± 3.2	90 ± 4

炎症因子	例数	T0	T1	T2	T3	T4	T5
IL?1_Dex组	30	2.56 ± 0.30	2.66 ± 0.26	8.51 ± 0.47^ae	14.28 ± 0.63^be	8.96 ± 0.43^ce	5.00 ± 0.40^de
IL?1_对照组	30	2.59 ± 0.28	2.65 ± 0.27	12.34 ± 1.06^a	18.48 ± 1.06^b	13.24 ± 0.59^c	8.74 ± 0.64^d
IL?6_Dex组	30	8.88 ± 0.98	8.96 ± 0.87	62.91 ± 8.35^ae	84.01 ± 5.47^be	54.26 ± 4.58^ce	23.65 ± 6.87^de
IL?6_对照组	30	9.21 ± 0.88	9.19 ± 0.64	72.29 ± 4.89^a	97.36 ± 5.45^b	62.34 ± 5.02^c	30.89 ± 7.02^d
hs?CRP_Dex组	30	1.67 ± 0.49	1.65 ± 0.54	7.56 ± 1.56^ae	11.25 ± 3.58^be	8.54 ± 2.56^ce	3.98 ± 0.87^de
hs?CRP_对照组	30	1.63 ± 0.50	1.64 ± 0.59	11.25 ± 2.24^a	16.27 ± 4.21^b	13.65 ± 3.45^c	8.24 ± 2.31^d
TNF?α_Dex组	30	3.32 ± 0.52	3.25 ± 0.49	10.23 ± 2.14^ae	15.26 ± 3.57^be	13.46 ± 3.64^ce	7.25 ± 2.58^de
TNF?α_对照组	30	3.39 ± 0.78	3.37 ± 0.51	14.36 ± 2.56^a	19.57 ± 4.25^b	16.54 ± 4.21^c	11.57 ± 3.24^d

炎症因子	例数	T0	T1	T2	T3	T4	T5
IL?1_Dex组	30	2.56 ± 0.30	2.66 ± 0.26	8.51 ± 0.47^ae	14.28 ± 0.63^be	8.96 ± 0.43^ce	5.00 ± 0.40^de
IL?1_对照组	30	2.59 ± 0.28	2.65 ± 0.27	12.34 ± 1.06^a	18.48 ± 1.06^b	13.24 ± 0.59^c	8.74 ± 0.64^d
IL?6_Dex组	30	8.88 ± 0.98	8.96 ± 0.87	62.91 ± 8.35^ae	84.01 ± 5.47^be	54.26 ± 4.58^ce	23.65 ± 6.87^de
IL?6_对照组	30	9.21 ± 0.88	9.19 ± 0.64	72.29 ± 4.89^a	97.36 ± 5.45^b	62.34 ± 5.02^c	30.89 ± 7.02^d
hs?CRP_Dex组	30	1.67 ± 0.49	1.65 ± 0.54	7.56 ± 1.56^ae	11.25 ± 3.58^be	8.54 ± 2.56^ce	3.98 ± 0.87^de
hs?CRP_对照组	30	1.63 ± 0.50	1.64 ± 0.59	11.25 ± 2.24^a	16.27 ± 4.21^b	13.65 ± 3.45^c	8.24 ± 2.31^d
TNF?α_Dex组	30	3.32 ± 0.52	3.25 ± 0.49	10.23 ± 2.14^ae	15.26 ± 3.57^be	13.46 ± 3.64^ce	7.25 ± 2.58^de
TNF?α_对照组	30	3.39 ± 0.78	3.37 ± 0.51	14.36 ± 2.56^a	19.57 ± 4.25^b	16.54 ± 4.21^c	11.57 ± 3.24^d

Please choose a citation manager

Content to export